MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • August 2026

AIVITA Biomedical Publishes a Universal Dendritic Cell Cancer Vaccine Platform

AIVITA Biomedical Strengthens Board of Directors with Appointment of Global Health and Vaccine Readiness Leader Larry Brilliant

AIVITA Biomedical Nominated for 2026 Prix Galien USA Award

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target infectious diseases and tumor-initiating cells — the seed of all cancers — using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Publishes a Universal Dendritic Cell Cancer Vaccine Platform
  • AIVITA Biomedical Strengthens Board of Directors with Appointment of Global Health and Vaccine Readiness Leader Larry Brilliant
  • AIVITA Biomedical Nominated for 2026 Prix Galien USA Award
  • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
  • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.